Cargando…
A Randomized, Multicenter, Double-Blind, Parallel, Non-Inferiority Clinical Study to Compare the Efficacy and Safety of Unicenta and Melsmon for Menopausal Symptom Improvement
This study was conducted to evaluate the efficacy and safety of Unicenta in female subjects with menopausal symptoms by analyzing the changes in the Kupperman index (primary endpoint) and hormonal changes (secondary endpoint). It was a randomized, multi-center, double-blind, parallel, non-inferiorit...
Autores principales: | Kim, Seongmin, Lee, Sanghoon, Ahn, Ki-Hoon, Park, Hyun-Tae, Song, Jae-Yun, Hong, Soon-Cheol, Kim, Tak |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10456340/ https://www.ncbi.nlm.nih.gov/pubmed/37629679 http://dx.doi.org/10.3390/medicina59081382 |
Ejemplares similares
-
Efficacy and safety of equine cartilage for rhinoplasty: a multicenter double-blind non-inferiority randomized confirmatory clinical trial
por: Chang, Yongjoon, et al.
Publicado: (2022) -
Comparison of the efficacy and safety of CELBESTA® versus CELEBREX® in patients with rheumatoid arthritis: a 6-week, multicenter, double-blind, double-dummy, active-controlled, randomized, parallel-group, non-inferiority phase 4 clinical trial
por: Kim, Hyun-Sook, et al.
Publicado: (2020) -
Effects of Chlorogenic Acids on Menopausal Symptoms in Healthy Women: A Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Trial
por: Enokuchi, Yuka, et al.
Publicado: (2020) -
Icenticaftor, a CFTR Potentiator, in COPD: A Multicenter, Parallel-Group, Double-Blind Clinical Trial
por: Martinez, Fernando J., et al.
Publicado: (2023) -
Zabofloxacin versus moxifloxacin in patients with COPD exacerbation: a multicenter, double-blind, double-dummy, randomized, controlled, Phase III, non-inferiority trial
por: Rhee, Chin Kook, et al.
Publicado: (2015)